I agree that ONXX should rise tomorrow, but one never knows. I thought the earnings reports was very good. 2013 could be a very exciting year for ONXX shareholders.
Not sure why you put the word "authors" in quotation marks. Don't you think the people who posted their thoughts wrote them, or is it that you lack basic understand of english? I post what I think, not to try and convince others or myself that my investment to buy or hold ONXX is the right move.
Hey Andy, kind of hypocritical of you there attacking as you are attacking ONXX longs. You seem to be belittling those of us who choose to buy a stock and wait, in this case ONXX. I see you fancy yourself as a sophisticated investor rather than the "common" buy and hold type. I do understand why someone would buy calls or puts to hedge their bets. I have never mocked or belittled anyone for #$%$ so. However, I would venture it is a losing strategy in the long run as you cost yourself money in the attempt to hedge your bets. I place it as being akin to someone who buys insurance in a casino when they have blackjack thinking it is a wise move because they guarantee themselves a profit. In reality, they cost themselves money as they give way their edge an consequently cost themselves 1/13 of each bet in the long run. Good luck to you.
nidan, I like the way you think. I would sure as hell be a lot happier with ONXX back to $90. Looks like today is a nice start on that ride.
Thanks John but odibro was the one who made the first prediction of ONXX's rise today. Frankly I don't care who gets credit, I just want to enjoy the rise today. It was getting a bit nerve racking watching the steep decline in share price.
Whether or not SNTA's share price goes up or down today is anybody's guess. Based on your perfect record on predictions about SNTA, you are always wrong. Since you predict a share price decline today and you are the perfect contrarian indicator, I predict that SNTA will rise today.
Definitely good news and a bit of a relief to see FDA approval. I was fortunate to have gotten in after the FDA denied approval last time on essentially a technicality. Now we can sit back and see how quickly T-DM1 penetrates the breast cancer market. It will also be interesting to see T-DM1 expand into other cancer types were HER2 over-expression is detected, which should be in some ovarian cancers.
sheik, You are one of the worst pumping offenders. This isn't a recent phenomenon but you have been one for a long long time. Everything I said was factually accurate. Which is in stark contrast to the BS were spouting complete non-sense. This includes your laughable such as the safe as sugar BS. I also laughed a lot at your comment that efficacy in reversing a short term chemically induced fibrosis in young healthy mice means GALT's fibrosis drug will be success in humans. That is pumping of the highest order and it is what I have come to expect from you. If you had a shred of decency, you would be ashamed of your actions, whether they the result of ignorance or your blatant lying to pump up GALT stock. Too bad if you don't like it. I find your actions despicable and they deserve a swift and firm rebuttal. I never said that GALT's fibrosis drug will definitely fail. I said it is far too soon to get even a hint of its chances. It will take a long time to find out.
You keep posting as if Ludwig's use of Davanat is a slam dunk. I posed this challenge to both you and the other pumper Hudson more than once and am still waiting for a reply. Tell me exactly why you think the Ludwig-Davanat pre-clinical data is so strong, then I will tell you why it is very weak. I am waiting. Why do you and Hudson remain silent?
Nidan, the FDA decision on Regorafenib in third line metastatic colon cancer is due shortly. Maybe that is what is making Coles giddy. The trials where Kyprolis is going for 2nd line or even better, first line vs Velcade head to head is what will really drive ONXX higher.
I like the way you thnik, but there are a lot of ADC drugs being tested so I doubt PSMA-ADC will be third. I just want it to show good efficacy in phase II at the 2.5 dose and someday get approved.
You are a funny guy. What is a fake bounce? Do you mean this stock price didn't really rise because it is a typo present in all the media releases?
Why are you babbling about stock price? I am talking about facts and science, and calling out the pumpers on the BS and lies that they are spewing. Get it? Unless, you really believe that complete non-sense that one pumper actually posted. You know where that pumper stated that the mouse genome is the closest to humans so that is why it is used for pre-clinical work.
Are you clueless or just a pumper? I am talking about pumpers lying and misrepresenting data and risk. All my statements have been factually accurate, and you know this is true because you haven't countered any of them but rather stooped to accusing me of being jealous or wanting to get into GALT at a lower price. That is a laugh. I would never buy GALT at any price. I own real companies with real products and real data, like ONXX not hype drive companies like GALT. Did you notice the lying pumpers still haven't responded to my challenge, to explain why they think the limited pre-clinical data from Ludwig is strong, when it is clearly trivial and weak.
You are talking about stock price driven by NO data. I am pleased that the stock has risen because people who have been mislead by the lying pumpers and the company may be able to recover some of their losses now. Azgranny being the one I am most happy for now. Looks like we have the classic great fool theory being played out now with GALT. We know where you fit in that. Hey the GALT price may go up even more because there are a lot of greedy fools out there.
Sentiment: Strong Sell
Just keep flagging EVERY single post that is part of the spamming. This means the original post as well as the imbeciles agreeing to it. Hopefully if enough people do s , Yahoo will pull them. The sad thing is that this type of spamming is going on now on most of the message boards I frequent .
It was a bit surprising that ONXX didn't even get a small bump on the Regorafenib approval for GIST. Maybe it came too soon on the heels for the big rise earlier in the week after the earnings report. In any event, it is nice to see that additional revenue will be coming into ONXX. With regards to Regorafenib, I am not sure what the time table is for its approval in Europe for either mCRC or GIST is, but that will be welcome news when it comes. Bayer also has Regorafenib in a large number of trials so more indication where it is efficacious may be coming down the line.